Director, Value & Outcomes Liaison

Title:

Director, Value & Outcomes Liaison

Location:

Remote

We are seeking a Director, Value & Outcomes Liaison who will report to the Senior Director, Head of Health Economics & Outcomes Research. You will serve as a field-based scientific expert responsible for communicating Celcuity’s clinical, real-world, and health economic evidence to U.S. payer and healthcare decision-making audiences.

This individual contributor role will focus on building trusted relationships through compliant, evidence-based scientific exchange to support optimal patient access to Celcuity’s innovative oncology therapies. The Director, VOL will work collaboratively across Medical Affairs, Market Access, and HEOR teams to ensure insights from the field inform Celcuity’s evidence generation priorities, value communication strategy, and payer/population healthcare decision-maker engagement planning.

• Serve as a field-based scientific liaison to engage population‑health decision makers (PHDMs), including payers, pathway organizations, health systems, research institutions, and policy makers – engaging in clinical, scientific, and health economic exchange for gedatolisib in studied/approved disease areas.
• Support Market Access and Medical Affairs colleagues through evidence communication, PHDMs insight generation, and cross‑functional collaboration to inform access strategies.
• Establish valued relationships with PHDMs within assigned accounts and maintain an understanding of the access landscape including P&T formulary inclusion, pathway development, payer medical policy coverage, and emerging competitive trends.
• Proactively represent the evidence needs of PHDMs to internal stakeholders to guide HEOR planning real‑world evidence (RWE) strategies, and account planning.
• Identify opportunities for and support collaborative research and data generation partnerships in real‑world evidence and outcomes research.
• Maintain deep expertise in relevant oncology disease areas, PHDM landscape dynamics, and HEOR/RWE methodologies.
• Provide internal training and education on health economics and outcomes research concepts to Medical Affairs, Access, and cross‑functional teams.
• Contribute scientific expertise and field insights during scientific congresses, advisory boards, and other key engagements (e.g., pre‑approval information exchange).
• Other duties as assigned.

• Advanced degree (PhD, Pharm
  
  D, MD, MPH, or equivalent) in a relevant scientific or health‑related discipline.
• Eight plus (8+) years of relevant experience in the pharmaceutical, biotechnology, or healthcare industry, including eight plus (8+) years of oncology/hematology experience and field‑based customer‑facing roles in industry.
• Demonstrated experience in field‑based scientific, PHDM/payer, or HEOR roles with a strong understanding of PHDM/payer evidence needs.
• Solid understanding of HEOR principles, study design, and the U.S. healthcare access environment.
• Demonstrated expertise in HEOR (including observational and pharmacoeconomic research) and value assessment which may include experience using RWE studies and pharmacoeconomic models under FDAMA 114.
• Excellent leadership and cross‑functional collaboration skills, with ability to influence and drive strategy across teams.
• Excellent verbal, written, and presentation skills, with demonstrated interpersonal and relationship‑building capabilities.
• Highly motivated, self‑directed professional who thrives in a fast‑paced, collaborative biotech environment.
• Maintain a positive, approachable and professional attitude.

Celcuity is a clinical‑stage, publicly traded biotechnology company seeking to extend the lives of cancer patients through the development of targeted therapies for the treatment of multiple solid tumor indications. The company was founded to develop a better way to treat the cellular drivers of tumor growth.

Our lead therapeutic candidate, gedatolisib, is an intravenously administered, potential first‑in‑class PI3K/AKT/mTOR (PAM) pathway inhibitor. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational…